Fig. 7. Vaccination with AMP-CpG induces durable gp350-specific IgG responses.

HLA-B*35:01 transgenic mice (n = 9 per vaccine group and n = 5 per control group) were immunized at weeks 0, 3, and 6 with 40 μg EBVpoly and 10 μg gp350 proteins admixed with 1.2 nmol AMP-CpG. The control group was immunized with AMP-CpG alone. Humoral responses to gp350 were assessed in splenocytes and serum from immunized mice at week 7 by ASC ELISPOT or ELISA assay. Shown are a ex vivo ASC ELISPOT measured frequency of gp350-specific ASCs per 3 × 10⁵ splenocytes, b week 31 ex vivo ASC recall response to a recall vaccination at week 30, c longitudinal serum IgG titers, d week 31 IgG titers to a recall vaccination at week 30, e longitudinal Ig subtype titers in pooled serum samples, and f week 31 recall EBV neutralization titers to a recall vaccination at week 30, compared to 29 pre-boost responses using pooled serum samples. Data are representative of one experiment. Values depicted are mean ± standard deviation. Black arrows indicate immunization days. Dotted lines in c, e indicate the assay LOD. *p < 0.05; **p < 0.01; ***p < 0.001 by two-sided Mann–Whitney test. The exact p-values are as follows. a AMP vaccine to AMP-CpG at week 4, 7, 21, and 29-0.0095. b Post recall to pre-recall-0.0004. c AMP vaccine to AMP-CpG at week 3, 4, 6, 7, 14, 21, 29-0.0095. d Post recall to pre-recall-0.0004. Source data are provided as a Source Data file.